Every Form 4 that Addex Therapeutics Ltd (ADXN) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ADXN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ADXN filings page.
Addex Therapeutics Ltd. (ADXN) reported that its principal accounting officer, Lenaic Nathanael Teyssedou, had multiple existing stock options adjusted on September 2, 2026. Several option awards previously carrying exercise prices including $0.160, $0.053, and $0.062 per share were reported as dispositions to the issuer and corresponding acquisitions of replacement options with an exercise price of $0.032 per share. All other terms of the options, including their original exercise and expiration dates, remain unchanged, and the transactions are described as exempt under Rule 16b-6(d) and Rule 16b-3.
Addex Therapeutics Ltd. (ADXN) reported administrative equity-compensation changes for officer Mikhail Kalinichev on September 2, 2026. The company recorded the disposition to the issuer and regrant of 200,000 stock options with the exercise price reduced from $0.062 to $0.032 per share, and reflected a related repricing for 306,765 shares previously acquired under a deferred strike price payment plan. Footnotes state all other option and plan terms remain unchanged and that the transactions were exempt under specified Exchange Act rules.
Addex Therapeutics Ltd. (ADXN) director Jason Raleigh Nunn reported compensation-related adjustments on September 2, 2026 with no net change in his positions. He returned and simultaneously re-received 219,561 shares of Common Stock and 50,000 stock options, reflecting the Remuneration Committee’s decision to reprice the related strike and exercise prices to $0.032 per share while leaving all other terms unchanged. No Rule 10b5-1 trading plan is reported.
Addex Therapeutics Ltd. (ADXN) reports that director and chief medical officer Roger Mills had existing equity awards economically repriced on September 2, 2026. The exercise/strike price on 392,837 shares of common stock acquired via prior option exercises and on related stock options over 50,000 shares was reduced to $0.032 per share following a Remuneration Committee decision, with all other terms unchanged. The paired dispositions and acquisitions on the Form 4 reflect this repricing and are reported as exempt under Rule 16b-6(d) and Rule 16b-3, with U.S. dollar amounts converted from Swiss francs at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026.
Addex Therapeutics Ltd. (ADXN) director Isaac Manke reported repricing equity incentives on September 2, 2026. An option covering 50,000 common shares and deferred strike obligations on 219,561 previously acquired shares were reset to an exercise or strike price of $0.032 per share, with all other terms unchanged and no net change in the number of shares or options held. These actions are described as exempt under Rule 16b-6(d) and Rule 16b-3 of the Exchange Act and were not made under a Rule 10b5-1 trading plan.
Addex Therapeutics Ltd. (ADXN) director Lawton Vincent Michael reported a repricing of equity incentives on September 2, 2026. Existing options for 501,598 shares of common stock were surrendered and a replacement option for the same 501,598 shares was granted, reducing the exercise price from $0.062 to $0.032 per share. In addition, 2,507,487 common shares previously acquired under a deferred strike price payment plan remain outstanding, with the strike price on all related units similarly reduced to $0.032. The company states that all other terms of the options and plan are unchanged and that these transactions are exempt under specified Exchange Act rules. No Rule 10b5-1 trading plan is reported.
Addex Therapeutics Ltd. (ADXN) reported that director Raymond George Hill had paired administrative transactions on September 2, 2026 to reflect repricing of previously granted equity awards. A total of 1,365,532 shares of common stock and options over 273,107 shares were recorded as dispositions to the issuer and simultaneous grants at a reduced exercise price of $0.032 per share, while all other terms of the plans and options remained unchanged. No Rule 10b5-1 trading plan is reported.
Addex Therapeutics Ltd. (ADXN) reported that chief executive officer and director Timothy Mark Dyer had his equity awards economically repriced on September 2, 2026, without any net change in the number of shares he holds. The Form 4 shows paired dispositions to and acquisitions from the issuer that reflect this repricing mechanics.
The filing covers 16,413,787 shares of common stock acquired previously through a deferred strike price payment plan and 3,369,796 stock options. For the deferred strike plan units, initial strike prices of $0.16 and $0.053 per share were reduced to $0.032 per share following a Remuneration Committee decision, with all other terms unchanged. Separately, the exercise price of the covered options was reduced from $0.062 to $0.032 per share, with no cash changing hands in these reporting entries.
The company states that these transactions are exempt under Rule 16b-6(d) and Rule 16b-3 under the Exchange Act. Exercise and strike prices are reported in U.S. dollars based on an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026.